AP3250A - Tablets for combination therapy - Google Patents

Tablets for combination therapy

Info

Publication number
AP3250A
AP3250A AP2011005857A AP2011005857A AP3250A AP 3250 A AP3250 A AP 3250A AP 2011005857 A AP2011005857 A AP 2011005857A AP 2011005857 A AP2011005857 A AP 2011005857A AP 3250 A AP3250 A AP 3250A
Authority
AP
ARIPO
Prior art keywords
tablets
combination therapy
therapy
combination
Prior art date
Application number
AP2011005857A
Other languages
English (en)
Other versions
AP2011005857A0 (en
Inventor
Joanna M Koziara
Reza Oliyal
Mark M Menning
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2011005857A0 publication Critical patent/AP2011005857A0/xx
Application granted granted Critical
Publication of AP3250A publication Critical patent/AP3250A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2011005857A 2009-02-06 2010-02-04 Tablets for combination therapy AP3250A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06
PCT/US2010/023226 WO2010091197A2 (en) 2009-02-06 2010-02-04 Tablets for combination therapy

Publications (2)

Publication Number Publication Date
AP2011005857A0 AP2011005857A0 (en) 2011-10-31
AP3250A true AP3250A (en) 2015-05-31

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005857A AP3250A (en) 2009-02-06 2010-02-04 Tablets for combination therapy

Country Status (31)

Country Link
US (2) US20100285122A1 (pl)
EP (1) EP2393485B1 (pl)
JP (2) JP5611242B2 (pl)
KR (2) KR101645759B1 (pl)
CN (1) CN102307573B (pl)
AP (1) AP3250A (pl)
AR (1) AR075369A1 (pl)
AU (1) AU2010210598B2 (pl)
BR (1) BRPI1008664A2 (pl)
CA (1) CA2750521A1 (pl)
CL (1) CL2011001885A1 (pl)
CY (1) CY1116852T1 (pl)
DK (1) DK2393485T3 (pl)
EA (2) EA030123B1 (pl)
EC (1) ECSP11011307A (pl)
ES (1) ES2548886T3 (pl)
HK (1) HK1164737A1 (pl)
HR (1) HRP20151009T1 (pl)
HU (1) HUE025822T2 (pl)
IL (1) IL214227A (pl)
MX (1) MX2011008289A (pl)
NZ (1) NZ594214A (pl)
PE (1) PE20110994A1 (pl)
PL (1) PL2393485T3 (pl)
PT (1) PT2393485E (pl)
SG (3) SG173544A1 (pl)
SI (1) SI2393485T1 (pl)
SM (1) SMT201500266B (pl)
TW (1) TWI444367B (pl)
UY (1) UY32424A (pl)
WO (1) WO2010091197A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2602784T3 (es) * 2007-02-23 2017-02-22 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
AU2009242451C1 (en) * 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
US10857102B2 (en) 2010-11-19 2020-12-08 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
ES2744926T3 (es) * 2010-11-29 2020-02-26 Formac Pharmaceuticals N V Formulaciones comprimidas de sílices mesoporosas ordenadas
HUE035241T2 (en) * 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
HRP20161696T4 (hr) 2011-08-16 2023-10-13 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat
CN104105484A (zh) * 2012-02-03 2014-10-15 吉联亚科学公司 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CA2865491A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
PT3608325T (pt) 2012-12-21 2022-10-17 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
PL3316868T3 (pl) 2015-06-30 2020-10-19 Gilead Sciences, Inc. Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
WO2017134089A1 (en) 2016-02-02 2017-08-10 Sandoz Ag Crystalline forms of tenofovir alafenamide monofumarate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176220B2 (en) * 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
DE602006015721D1 (de) * 2005-12-14 2010-09-02 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
AU2007275860C1 (en) * 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176220B2 (en) * 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FOR THE UK COLLABORATIVE HIV COHORT (CHIC) STUDY PHILLIPS ET AL.: "Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 370, no. 9603, 6 December 2007 (2007-12-06), pages 1923-1928, XP022379072, ISSN: 0140-6736, the whole document *
GERMAN P. ET AL.: "pharmacokinetics and bioavailability of an integrate and novel pharmacoenhancer-containing single tablet ixed dose combination", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, vol. 55, no. 3, 1 November 2010 (2010-11-01), pages 323-329, XP008134624, ISSN: 1525-4135, the whole document *
J. MARTINEZ-CAJAS ET AL.: "Antiretroviral therapy- Optimal sequencing of therapy to avoid resistance", DRUGS, vol. 68, no. 1, 2008, pages 43-72, XP8134919, the whole document *
L. SZCZECH: "Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context", THE JOURNAL OF INFECTIOUS DISEASES, vol. 197, no. 1, 2008, pages 7-9, XP002630507, the whole document *
S. HAMMER ET AL.: "Antiretroviral treatment of adult HIV infection. 2008 Recommendations of the International AIDS Society- USA panel.", JAMA, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 300, no. 5, 2008, pages 555-570, XP8134902, the whole document *
V. VON WYL ET AL.: "Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment", ARCHIVES OF INTERNAL MEDICINE, vol. 167, no. 16, 2007, pages 1782-1790, XP002630508, the whole document *

Also Published As

Publication number Publication date
KR20160093100A (ko) 2016-08-05
JP2014221845A (ja) 2014-11-27
HRP20151009T1 (hr) 2015-10-23
PT2393485E (pt) 2015-10-23
US20100285122A1 (en) 2010-11-11
IL214227A0 (en) 2011-09-27
KR101738325B1 (ko) 2017-05-19
US20150150810A1 (en) 2015-06-04
JP5611242B2 (ja) 2014-10-22
DK2393485T3 (en) 2015-10-26
EA201190125A1 (ru) 2012-01-30
SI2393485T1 (sl) 2015-10-30
CL2011001885A1 (es) 2012-05-25
PE20110994A1 (es) 2012-01-24
BRPI1008664A2 (pt) 2016-03-08
MX2011008289A (es) 2011-09-15
CN102307573B (zh) 2013-09-11
SMT201500266B (it) 2016-01-08
PL2393485T3 (pl) 2015-12-31
AU2010210598B2 (en) 2015-03-05
HUE025822T2 (en) 2016-04-28
EA030123B1 (ru) 2018-06-29
IL214227A (en) 2017-01-31
AP2011005857A0 (en) 2011-10-31
ECSP11011307A (es) 2011-10-31
HK1164737A1 (en) 2012-09-28
NZ594214A (en) 2013-05-31
EP2393485B1 (en) 2015-07-29
CN102307573A (zh) 2012-01-04
SG2014007744A (en) 2014-05-29
CY1116852T1 (el) 2017-04-05
KR101645759B1 (ko) 2016-08-04
TWI444367B (zh) 2014-07-11
JP2012517432A (ja) 2012-08-02
AR075369A1 (es) 2011-03-30
AU2010210598A1 (en) 2011-08-25
WO2010091197A3 (en) 2011-06-03
ES2548886T3 (es) 2015-10-21
WO2010091197A2 (en) 2010-08-12
SG10201706215UA (en) 2017-08-30
SG173544A1 (en) 2011-09-29
CA2750521A1 (en) 2010-08-12
EP2393485A2 (en) 2011-12-14
JP5911927B2 (ja) 2016-04-27
UY32424A (es) 2010-09-30
EA201491658A1 (ru) 2015-05-29
TW201040142A (en) 2010-11-16
EA021313B1 (ru) 2015-05-29
KR20110122729A (ko) 2011-11-10

Similar Documents

Publication Publication Date Title
AP3250A (en) Tablets for combination therapy
GB0916335D0 (en) Medicaments
GB0909680D0 (en) Dosage form
ZA201200761B (en) Tablet
EP2427183A4 (en) THERAPEUTIC COMPOUNDS
GB0922589D0 (en) Pharmaceutical compounds
AU330360S (en) Tablet
GB0900484D0 (en) Therapeutic agent
EP2496704A4 (en) THERAPEUTIC COMPOUNDS
GB0920041D0 (en) Tablet
GB0915319D0 (en) Combination medicament
GB0916997D0 (en) Combination therapy
GB0908905D0 (en) Pharmaceutical compounds
EP2456309A4 (en) THERAPEUTIC COMPOUNDS
GB0906026D0 (en) Therapeutic compounds
GB0907973D0 (en) Combination therapy
GB0916332D0 (en) Medicaments
GB0916308D0 (en) Therapeutic compounds
GB0900712D0 (en) Therapeutic compounds
GB0911266D0 (en) Therapeutic compounds
GB0916608D0 (en) Therapeutic compounds
GB0914820D0 (en) WATerian therapy
GB0921244D0 (en) Therapy
GB0903319D0 (en) Therapy
GB0903321D0 (en) Therapy